Clearside Biomedical, Inc. to Present at the 2016 Stifel Healthcare Conference on Wednesday, November 16, 2016
November 08, 2016 16:30 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Names Rick McElheny as Vice President, Business Development
November 08, 2016 07:00 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. to Report Third Quarter 2016 Financial Results and Host Conference Call on Wednesday, November 9, 2016
November 02, 2016 07:00 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting
October 10, 2016 07:00 ET
|
Clearside Biomedical, Inc.
Phase 2 Results in the Treatment of Macular Edema Associated with Retinal Vein Occlusion Phase 2 and Phase 1/2 Results in the Treatment of Macular Edema Associated with Non-Infectious Uveitis ...
Clearside Biomedical, Inc. Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion
July 26, 2016 07:30 ET
|
Clearside Biomedical, Inc.
78% of Patients Required No Additional Treatment in the Trial Arm with Concomitant Suprachoroidally Administered Zuprata™ and Intravitreally Administered Eylea®Patients Reached an Average BCVA...